MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
IQV stock logo

IQV

IQVIA Holdings Inc.

$261.75
-0.63
 (-0.24%)
Exchange:  NYSE
Market Cap:  43.084B
Shares Outstanding:  125.468M
Delayed data
Calculate IQV Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Diagnostics & Research
   
CEO:  Ari Bousbib
Full Time Employees:  94000
Address: 
2400 Ellis Road
Durham
NC
27703
US
Website:  https://www.iqvia.com
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company’s operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA’s diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/05 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue14,984,00015,405,00016,310,000
Gross Profit5,239,0005,375,0004,286,000
EBITDA3,256,0003,453,0003,464,000
Operating Income1,977,0002,202,0002,287,000
Net Income1,358,0001,373,0001,360,000

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets26,681,00026,899,00029,944,000
Total Liabilities20,569,00020,832,00023,314,000
Total Stockholders Equity6,112,0006,067,0006,503,000
Total Debt13,896,00014,156,00016,174,000
Cash and Cash Equivalents1,376,0001,702,0001,980,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow2,149,0002,716,0002,654,000
Capital Expenditure-649,00000
Free Cash Flow1,500,0002,716,0002,654,000
Net Income1,358,0001,373,0001,361,000
Net Change in Cash160,000326,000278,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)22,021,874.363Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)22,822,807.430Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)22,248,500Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)4,647,245.279Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)4,816,265.061Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)4,695,069.769Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)3,557,588.025Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)3,726,315.041Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)3,605,330.020Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)2,969,269.729Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)3,077,261.732Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)2,999,826.286Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)20.780Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)21.480Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)20.500Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)6Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)3Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
15.405B  ?P/S
 (TTM)
: 
2.52
?Net Income
 (TTM)
: 
1.373B  ?P/E
 (TTM)
: 
31.96
?Enterprise Value
 (TTM)
: 
57.098B  ?EV/FCF
 (TTM)
: 
21.85
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
21.95%  ?ROIC
 (TTM)
: 
8.32%
?Net Debt
 (TTM)
: 
12.636B  ?Debt/Equity
 (TTM)
: 
2.63
?P/B
 (TTM)
: 
7.04  ?Current Ratio
 (TTM)
: 
0.71

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
20.26Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates IQV intrinsic value between $217.91 – $231.26 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about IQV valuation

Is IQVIA Holdings Inc. (IQV) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for IQVIA Holdings Inc. (IQV) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is IQV a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether IQV trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is IQV’s P/E ratio?

You can see IQV’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for IQV?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is IQV a good long-term investment?

Whether IQV fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

IQV

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.24
MARKETSnap

Trading Metrics:

Open: 260.55   Previous Close: 262.38
Day Low: 258.08   Day High: 262.81
Year Low: 154.5   Year High: 265.25
Price Avg 50: 219.43   Price Avg 200: 200.53
Volume: 1.842M   Average Volume: 1.578M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
27-08-2026 12:35
Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
BlackRock Inc. Takes Position in IQVIA Holdings Inc. $IQV
20-08-2026 03:24
BlackRock Inc. Takes Position in IQVIA Holdings Inc. $IQV
IQV Stock Gains 42% in 3 Months: Here's What You Should Know
12-08-2026 10:10
IQV Stock Gains 42% in 3 Months: Here's What You Should Know
Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?
04-08-2026 13:36
Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?
Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last
04-08-2026 13:01
Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last
IQVIA: A Great Business At The Wrong Price (Rating Downgrade)
29-07-2026 09:59
IQVIA: A Great Business At The Wrong Price (Rating Downgrade)

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read